Cochlear-Oticon merger inquiry
- DT Economics
- Dec 21, 2022
- 1 min read
Our managing partner, David Thomas, was today appointed to the Phase 2 inquiry group for this anticipated merger in the hearing implant sector.
The CMA has referred the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical, for an in-depth investigation. This assessment will identify whether this merger has resulted, or could result, in a substantial lessening of competition within a market or markets in the United Kingdom.
Further details on the CMA's case page:
Comentários